Amphastar Pharmaceuticals, Inc. (AMPH): Floyd F. Petersen , director of Amphastar Pharmaceuticals, Inc. sold 3,000 shares on Sep 8, 2016. The Insider selling transaction was reported by the company on Sep 12, 2016 to the Securities and Exchange Commission. The shares were sold at $19.05 per share for a total value of $57,150.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 2, 2016, Howard Lee (director) sold 10,381 shares at $18.78 per share price.On Aug 24, 2016, Jason B. Shandell (President and General Counsel) sold 10,000 shares at $19.95 per share price.Also, On Aug 19, 2016, Richard K Prins (director) sold 3,086 shares at $19.62 per share price.On Aug 19, 2016, Diane G. Gerst (EVP, QA & Regulatory Affairs) sold 24,046 shares at $19.28 per share price.
Amphastar Pharmaceuticals Inc: On Monday, Sep 12, 2016 heightened volatility was witnessed in Amphastar Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $18.03 and hit $18.56 on the upside , eventually ending the session at $18.4, with a gain of 1.38% or 0.25 points. The heightened volatility saw the trading volume jump to 418,280 shares. The 52-week high of the share price is $21.16 and the company has a market cap of $830 M . The 52-week low of the share price is at $10.5.
Company has been under the radar of several Street Analysts.Amphastar Pharmaceuticals Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 22 from a previous price target of $20 .The Rating was issued on Aug 9, 2016.
Amphastar Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing manufacturing marketing and selling technically-challenging generic and injectable and inhalation products. The Company has two operational segments: finished pharmaceutical products and active pharmaceutical ingredients (API products). The finished pharmaceutical products segment manufactures markets and distributes enoxaparin Cortrosyn naloxone lidocaine jelly as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 17 products and is developing a portfolio of approximately 13 generic and eight injectable and inhalation product candidates. In addition to its marketed products it has a pipeline of approximately 21 generic and product candidates in various stages of development which target a variety of indications.